// App-Quantinova.ai

OP0221 (2022) : EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA)

Researchers

Presenter

  • N. Ruperto

Principal Investigators

  • E. Chertok

  • J. Dehoorne

  • G. Horneff

  • T. Kallinich

  • I. Louw

  • S. Compeyrot-Lacassagne

  • B. Lauwerys

  • N. Martin

  • K. Marzan

  • W. Knibbe

  • R. Martin

  • X. Zhu

  • S. Whelan

  • L. Pricop

  • A. Martini

  • D. J. Lovell

  • H. Brunner

Medical Centers

  • IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy

  • Voronezh State Medical University, Voronezh, Russian Federation

  • University Hospital Gent, Paediatrics, Gent, Belgium

  • Asklepios Klinik Sankt Augustin GmbH, General Paediatrics and Neonatology, Sankt Augustin, Germany

  • Charité - Universitätsmedizin Berlin, Paediatric Rheumatology, Berlin, Germany

  • Panaroma Medical Centre, Paediatrics, Cape Town, South Africa

  • Yorkhill Hospital, Paediatric Rheumatology, Glasgow, United Kingdom

  • Children’s Hospital Los Angeles, Rheumatology, Los Angeles, United States of America

  • St Lukes Intermountain Research Center, Rheumatology, Boise, United States of America

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Novartis Pharmaceuticals Corporation, Department of Biostatistics, East Hanover, United States of America

  • Novartis Ireland Ltd., Department of Clinical Development, Dublin, Ireland

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Università di Genova, Department of Pediatric Rheumatology, Genova, Italy

  • Cincinnati Children’s Hospital, University of Cincinnati, UC Department of Pediatrics, Cincinnati, United States of America

Locations

  • Italy

  • Russia

  • Belgium

  • Germany

  • South Africa

  • United Kingdom

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Rheumatoid arthritis

  • Spondyloarthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Telomerase reverse transcriptase

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved